|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Aurora kinase A and B have essential and non-overlapping roles in mitosis, with elevated expression in a subset of human cancers, including acute myeloid leukemia (AML).
|
30266802 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Rescue experiment showed that AURKA attenuated the influence of lncRNA TUG1 on AML cell proliferation and apoptosis.
|
29654398 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this phase 1 study, we investigated the safety and efficacy of AMG 900, an orally administered, highly potent, selective, small-molecule inhibitor of both Aurora kinase A and B, in patients with AML .
|
28370201 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia.
|
28034990 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our results provide evidence for AEG-1's carcinogenesis role in AML and reveal a novel functional link between AEG-1 and AURKA on Akt1 activation.
|
23499911 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of targeting the mitotic regulators aurora kinase A and B in pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
|
22940834 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that Aurora kinase A (AURKA) is aberrantly expressed in acute myelogenous leukemia (AML) cells when compared to bone marrow mononuclear cells isolated from healthy volunteers.
|
23686525 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study we investigated whether epitopes derived from Aurora kinase A and B are able to elicit cellular immune responses in patients with acute myeloid leukemia (AML) to investigate their role as potential targets for specific immunotherapy.
|
23101751 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we described a significant association between overexpression of AURKA/B and cytogenetics findings in AML, which may be relevant to new therapeutic approaches, based on Aurora kinase inhibitors.
|
20732714 |
2011 |